Can Tailored Antibiotics Shorten Endocarditis Therapy?
Traditional guidelines recommend prolonged antibiotic therapy lasting up to six weeks for patients with left-sided heart infections. However, modern evidence suggests that personalizing infective endocarditis treatment can improve patient outcomes while reducing hospital stay. The multicenter POET-II trial evaluated whether a response-tailored antibiotic strategy could safely shorten total therapy duration in clinically stable patients.
Evaluating the POET-II Clinical Trial Design
In this international open-label randomized trial, investigators enrolled 508 adults with left-sided endocarditis caused by streptococci, Enterococcus faecalis, or staphylococci. Before randomization, all participants completed two to four weeks of antibiotic therapy and achieved clinical stabilization. Therefore, patients demonstrated normal temperature, falling inflammatory markers, and transesophageal echocardiographic stability. Researchers then assigned 255 patients to tailored therapy and 253 patients to standard duration therapy lasting four to six weeks.
Optimizing Infective Endocarditis Treatment Duration
Patients in the tailored therapy group discontinued antibiotics immediately upon meeting stabilization criteria. Consequently, tailored therapy reduced total antibiotic duration by approximately two weeks. The median time alive and free of antibiotics within six months was 183 days for tailored therapy versus 169 days for standard therapy. Furthermore, the composite safety endpoint occurred in 8.2% of the tailored group compared to 10.7% of the standard group, meeting noninferiority criteria. Although slightly more relapses occurred in the tailored group, clinicians successfully treated them with antibiotic re-initiation.
Clinical Implications for Practice
These findings challenge decades of empirical consensus that mandated uniform, prolonged intravenous regimens. Consequently, clinicians can evaluate clinical and echocardiographic stability after two to four weeks of therapy. In addition, adopting an individualized strategy reduces hospital-acquired complications and antimicrobial resistance. As a result, tailored antibiotic management offers a practical framework for stable patients without compromising safety.
Frequently Asked Questions
Q1: What did the POET-II trial demonstrate about antibiotic duration?
The trial showed that a response-tailored antibiotic strategy safely reduced total treatment duration by two weeks in clinically stable patients with left-sided infective endocarditis.
Q2: Were safety outcomes compromised with shorter treatment?
No, the tailored strategy met noninferiority criteria for safety, showing similar rates of mortality, unplanned cardiac surgery, and embolic events compared to standard care.
Q3: Which pathogens were included in the study?
The trial evaluated adults with endocarditis caused by Streptococcus species, Enterococcus faecalis, or Staphylococcus species who achieved clinical stabilization.
References
- Bundgaard H et al. Response-Tailored or Standard-Duration Antibiotic Treatment for Infective Endocarditis. N Engl J Med. 2026 Aug 28. doi: 10.1056/NEJMoa2607887. PMID: 42663314.
- Iversen K, Ihlemann N, Gill SU, et al. Partial Oral versus Intravenous Antibiotic Treatment of Endocarditis. N Engl J Med. 2019;380(5):415-424.
- Delgado V, Ajmone Marsan N, de Waha S, et al. 2023 ESC Guidelines for the management of endocarditis. Eur Heart J. 2023;44(39):3948-4042.
